12
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The invasion process is a crucial step for pancreatic ductal adenocarcinoma ( PDAC); however, the genes related to invasion remain unclear. To identify specific genes for the invasion process, we compared microarray data for infiltrating cancer and Pan IN‐3, which were harvested from an individual PDAC patient by microdissection. Furthermore, immunohistochemical, coimmunoprecipitation and invasion analyses were performed to confirm the biologic significance of molecules identified by expression profile. In the present study, we focused on MUC16 and mesothelin among 87 genes that were significantly upregulated in infiltrating components compared to Pan IN‐3 in all PDAC patients, because MUC16 was the most differently expressed between two regions, and mesothelin was reported as the receptor for MUC16. Immunohistochemical analysis revealed that MUC16 and mesothelin were expressed simultaneously only in infiltrating components and increased at the invasion front, and binding of MUC16 and mesothelin was found in PDAC by immunoprecipitation assay. The downregulation of MUC16 by sh RNA and the blockage of MUC16 binding to mesothelin by antibody inhibited both invasion and migration of pancreatic cancer cell line. MUC16 high/mesothelin high expression was an independent prognostic factor for poor survival in PDAC patients. In conclusion, we identified two specific genes, MUC16 and mesothelin, associated with the invasion process in patients with PDAC. ( Cancer Sci 2012; 103: 739–746)

          Related collections

          Author and article information

          Journal
          Cancer Sci
          Cancer Sci
          10.1111/(ISSN)1349-7006
          CAS
          Cancer Science
          John Wiley and Sons Inc. (Hoboken )
          1347-9032
          1349-7006
          23 February 2012
          April 2012
          : 103
          : 4 ( doiID: 10.1111/cas.2012.103.issue-4 )
          : 739-746
          Affiliations
          [ 1 ] Second Department of Surgery Wakayama Medical University Wakayama
          [ 2 ] Department of Clinical Laboratory Medicine Wakayama Medical University Wakayama
          [ 3 ] Cancer Institute Japanese Foundation for Cancer Research Tokyo Japan
          Author notes
          [*] [* ] To whom correspondence should be addressed.

          E‐mail: seiko-h@ 123456wakayama-med.ac.jp

          Article
          PMC7659350 PMC7659350 7659350 CAS2214
          10.1111/j.1349-7006.2012.02214.x
          7659350
          22320398
          911bc2b9-05d7-4af3-8983-41681c27e3b4
          © 2012 Japanese Cancer Association
          History
          : 18 November 2011
          : 27 December 2011
          : 28 December 2011
          Page count
          Pages: 8
          Categories
          Original Article
          Original Articles
          Clinical Research
          Custom metadata
          2.0
          April 2012
          Converter:WILEY_ML3GV2_TO_JATSPMC version:5.9.3 mode:remove_FC converted:12.11.2020

          Comments

          Comment on this article